Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
The study is being done to determine the resection rate for subjects with pancreatic cancer after receiving gemcitabine, abraxane, 5-FU and radiation therapy.
1. Male or female age 18 or older
2. Confirmed adenocarcinoma of the pancreas
3. Tumors must be localized (not spread to other organs) and classified as borderline-resectable
4. No prior therapy for pancreatic cancer
5. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Treatment may continue until disease progression, unacceptable side effects, or withdrawal from the study. Follow-up will last for 5 years after last treatment.
Knight Clinical Trials Information Line
OHSU Knight Cancer Institute